NEW BRUNSWICK, N.J.,
Dec. 14, 2018 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today issued the
following statement regarding speculation about the safety of our
products.
The Reuters article is one-sided, false, and inflammatory.
Johnson & Johnson's baby powder is safe and asbestos-free.
Studies of more than 100,000 men and women show that talc does not
cause cancer or asbestos-related disease. Thousands of independent
tests by regulators and the world's leading labs prove our baby
powder has never contained asbestos. Johnson & Johnson will
continue to defend the safety of our product. For the truth and
facts about talc, please go to www.factsabouttalc.com.
The Reuters article is wrong in three key areas:
- The article ignores that thousands of tests by J&J,
regulators, leading independent labs, and academic institutions
have repeatedly shown that our talc does not contain
asbestos.
- The article ignores that J&J has cooperated fully and
openly with the U.S. FDA and other global regulators, providing
them with all the information they requested over decades. We have
also made our cosmetic talc mines and processed talc available to
regulators for testing. Regulators have tested both, and they have
always found our talc to be asbestos-free.
- The article ignores that J&J has always used the most
advanced testing methods available to confirm that our cosmetic
talc does not contain asbestos. Every method available to test
J&J's talc for asbestos has been used by J&J, regulators,
or independent experts, and all of these methods have all found
that our cosmetic talc is asbestos-free.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the
foundation of vibrant lives, thriving communities and forward
progress. That's why for more than 130 years, we have aimed to keep
people well at every age and every stage of life. Today, as the
world's largest and most broadly-based health care company, we are
committed to using our reach and size for good. We strive to
improve access and affordability, create healthier communities, and
put a healthy mind, body and environment within reach of everyone,
everywhere. We are blending our heart, science and ingenuity to
profoundly change the trajectory of health for humanity.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial
performance, product development, market position and business
strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including unexpected clinical trial results,
additional analysis of existing clinical data, uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of
commercial success for new and existing products; the impact of
business combinations and divestitures; challenges to patents; the
impact of patent expirations; the ability of the company to
successfully execute strategic plans, including restructuring
plans; manufacturing difficulties or delays, internally or within
the supply chain; product efficacy or safety concerns resulting in
product recalls or regulatory action; significant adverse
litigation or government action, including related to product
liability claims; changes to applicable laws and regulations,
including tax laws, global health care reforms and import/export
and trade laws; trends toward health care cost containment; changes
in behavior and spending patterns of purchasers of health care
products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny
of the health care industry by government agencies. A further list
and descriptions of these risks, uncertainties and other factors
can be found in Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended December 31,
2017, including in the sections captioned "Cautionary Note
Regarding Forward-Looking Statements" and "Item 1A. Risk Factors,"
in the company's most recently filed Quarterly Report on Form 10-Q
and in the company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Any forward-looking statement made in this release speaks
only as of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/statement-on-reuters-talc-article-300765830.html
SOURCE Johnson & Johnson